HIV-2 goes global: An unaddressed issue in Indian anti-retroviral programmes

Indian Journal of Medical Research

Volumn 132, Issue 12, 2010, Pages 660-662

  de Silva, Thushan ^a,b   Weiss, Robin A ^b  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; DARUNAVIR; EFAVIRENZ; INDINAVIR; INDINAVIR PLUS RITONAVIR; LAMIVUDINE; LOPINAVIR; NEVIRAPINE; SAQUINAVIR; TENOFOVIR; ZIDOVUDINE; ADENINE; DRUG DERIVATIVE; PHOSPHONIC ACID DERIVATIVE;

DRUG EFFICACY; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS 2 INFECTION; INDIA; NOTE; PANDEMIC; PREVALENCE; TREATMENT OUTCOME; HUMAN IMMUNODEFICIENCY VIRUS INFECTION;

ADENINE; ANTI-HIV AGENTS; HIV INFECTIONS; HIV-2; HUMANS; INDIA; PHOSPHONIC ACIDS; PREVALENCE; ZIDOVUDINE;

EID: 78751551287     PISSN: 09715916     EISSN: 09715916     Source Type: Journal    
DOI: None     Document Type: Note

References (19)

1. Chiara M, Rony Z, Homa M, Bhanumati V, Ladomirska J, Manzi M, et al. Characteristics, immunological response & treatment outcomes of HIV-2 compared with HIV-1 & dual infections (HIV-1/2) in Mumbai. Indian J Med Res 2010; 132: 683-9.
2. Kannangai R, Ramalingam S, Vijayakumar TS, Prabu K, Jesudason MV, Sridharan G. HIV-2 sub-epidemic not gathering speed: experience from a tertiary care center in South India. J Acquir Immune Defc Syndr 2003; 32: 573-5.
3. Kannangai R, Nair SC, Sridharan G, Prasannakumar S, Daniel D. Frequency of HIV type 2 infections among blood donor population from India: a 10-year experience. Indian J Med Microbiol 2010; 28: 111-3.
4. Available from: http://www.unaids.org/en/CountryResponses/Countries/india.asp, accessed on September 23, 2010
5. Poulsen AG, Aaby P, Gottschau A, Kvinesdal BB, Dias F, Molbak K, et al. HIV-2 infection in Bissau, West Africa, 1987-1989: incidence, prevalences, and routes of transmission. J Acquir Immune Defc Syndr 1993; 6: 941-8.
6. Pepin J, Plamondon M, Alves AC, Beaudet M, Labbe AC. Parenteral transmission during excision and treatment of tuberculosis and trypanosomiasis may be responsible for the HIV-2 epidemic in Guinea-Bissau. AIDS 2006; 20: 1303-11.
7. Lemey P, Pybus OG, Wang B, Saksena NK, Salemi M, Vandamme AM. Tracing the origin and history of the HIV-2 epidemic. Proc Natl Acad Sci USA 2003; 100: 6588-92.
8. da Silva ZJ, Oliveira I, Andersen A, Dias F, Rodrigues A, Holmgren B, et al. Changes in prevalence and incidence of HIV-1, HIV-2 and dual infections in urban areas of Bissau, Guinea-Bissau: is HIV-2 disappearing? AIDS 2008; 22: 1195-202.
9. Schim van der Loeff MF, Larke N, Kaye S, Berry N, Ariyoshi K, Alabi A, et al. Undetectable plasma viral load predicts normal survival in HIV-2-infected people in a West African village. Retrovirology 2010; 7: 46.
10. Schim van der Loeff MF, Jaffar S, Aveika AA, Sabally S, Corrah T, Harding E, et al. Mortality of HIV-1, HIV-2 and HIV-1/HIV-2 dually infected patients in a clinic-based cohort in The Gambia. AIDS 2002; 16: 1775-83.
11. Gottlieb GS, Sow PS, Hawes SE, Ndoye I, Redman M, Coll-Seck AM, et al. Equal plasma viral loads predict a similar rate of CD4+ T cell decline in human immunodefciency virus (HIV) type 1- and HIV-2-infected individuals from Senegal, West Africa. J Infect Dis 2002; 185: 905-14.
12. Masse S, Lu X, Dekhtyar T, Lu L, Koev G, Gao F, et al. In vitro selection and characterization of human immunodefciency virus type 2 with decreased susceptibility to lopinavir. Antimicrob Agents Chemother 2007; 51: 3075-80.
13. Desbois D, Roquebert B, Peytavin G, Damond F, Collin G, Benard A, et al. In vitro phenotypic susceptibility of human immunodefciency virus type 2 clinical isolates to protease inhibitors. Antimicrob Agents Chemother 2008; 52: 1545-8.
14. van der Ende ME, Prins JM, Brinkman K, Keuter M, Veenstra J, Danner SA, et al. Clinical, immunological and virological response to different antiretroviral regimens in a cohort of HIV-2-infected patients. AIDS 2003; 17 (Suppl 3): S55-61.
15. Ruelle J, Roman F, Vandenbroucke AT, Lambert C, Fransen K, Echahidi F, et al. Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral effcacy in HIV-2: analysis of the HIV-2 Belgium and Luxembourg database. BMC Infect Dis 2008; 8: 21.
16. Drylewicz J, Matheron S, Lazaro E, Damond F, Bonnet F, Simon F, et al. Comparison of viro-immunological marker changes between HIV-1 and HIV-2-infected patients in France. AIDS 2008; 22: 457-68.
17. Matheron S, Damond F, Benard A, Taieb A, Campa P, Peytavin G, et al. CD4 cell recovery in treated HIV-2-infected adults is lower than expected: results from the French ANRS CO5 HIV-2 cohort. AIDS 2006; 20: 459-62.
18. Jallow S, Kaye S, Alabi A, Aveika A, Sarge-Njie R, Sabally S, et al. Virological and immunological response to Combivir and emergence of drug resistance mutations in a cohort of HIV-2 patients in The Gambia. AIDS 2006; 20: 1455-8.
19. Gottlieb GS, Badiane NM, Hawes SE, Fortes L, Toure M, Ndour CT, et al. Emergence of multiclass drug-resistance in HIV-2 in antiretroviral-treated individuals in Senegal: implications for HIV-2 treatment in resouce-limited West Africa. Clin Infect Dis 2009; 48: 476-83.